A detailed history of Next Century Growth Investors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Next Century Growth Investors LLC holds 9,922 shares of VRTX stock, worth $4.65 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
9,922
Previous 6,187 60.37%
Holding current value
$4.65 Million
Previous $2.52 Million 64.76%
% of portfolio
0.37%
Previous 0.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$407.69 - $446.08 $1.52 Million - $1.67 Million
3,735 Added 60.37%
9,922 $4.15 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $2.23 Million - $2.67 Million
-6,501 Reduced 51.24%
6,187 $2.52 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $939,802 - $1.01 Million
2,779 Added 28.05%
12,688 $4.41 Million
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $64,859 - $73,989
-229 Reduced 2.26%
9,909 $3.12 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $2.9 Million - $3.26 Million
10,138 New
10,138 $2.93 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $1.69 Million - $2.25 Million
-8,144 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $266,642 - $316,133
-1,043 Reduced 11.35%
8,144 $2.22 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $1.64 Million - $2.2 Million
-9,811 Reduced 51.64%
9,187 $2.01 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $324,940 - $375,790
1,974 Added 11.6%
18,998 $3.48 Million
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $928,170 - $1.17 Million
6,110 Added 55.98%
17,024 $2.82 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $1.83 Million - $2.1 Million
10,914 New
10,914 $2.1 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Next Century Growth Investors LLC Portfolio

Follow Next Century Growth Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Next Century Growth Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Next Century Growth Investors LLC with notifications on news.